The constitutively active BCR-ABL tyrosine kinase is the defining molecular abnormality in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) [1–6]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.